For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Vitamin D + Fish Oil | Vitamin D: Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU Other Name: cholecalciferol Fish oil: Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]) | 7 | None | 18 | 66 | 16 | 66 | View |
| Vitamin D + Fish Oil Placebo | Vitamin D: Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU Other Name: cholecalciferol Fish oil placebo: Fish oil placebo | 4 | None | 20 | 75 | 16 | 75 | View |
| Vitamin D Placebo + Fish Oil | Fish oil: Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]) Vitamin D placebo: Vitamin D placebo | 7 | None | 28 | 82 | 17 | 82 | View |
| Vitamin D Placebo + Fish Oil Placebo | Vitamin D placebo: Vitamin D placebo Fish oil placebo: Fish oil placebo | 4 | None | 19 | 67 | 15 | 67 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Gastrointestinal bleeding | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Hypercalcemia | SYSTEMATIC_ASSESSMENT | Endocrine disorders | None | View |
| Malignant Cancer | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | None | View |
| Major CVD | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Easy bruising | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Frequent nosebleeds | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Blood in urine | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Parathyroid condition | SYSTEMATIC_ASSESSMENT | Endocrine disorders | None | View |
| Kidney failure or dialysis | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Stomach upset or pain | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Skin rash | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| Nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Constipation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Diarrhea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Bad taste in mouth | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Increased burping | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Kidney stones | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |